Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and (Nasdaq: BIIB, Corporate headquarters: Cambridge, ...

"Amyloid-lowering treatments represent an important advance in the treatment of Alzheimer's disease but they are associated ...

In recent years, the focus of clinical development has been on immunotherapeutic compounds aimed at clearing brain ...

Figure 1: A new W-shaped structural model of E22G 40-residue beta-amyloid fibrils. RIKEN researchers have shown how the ...

The technology – called Antibody Transport Vehicle (ATV): Amyloid beta – can be used to help amyloid-targeting drugs cross the blood brain barrier (BBB) more effectively, say the partners.

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

In a small early trial using a transcranial magnetic stimulation procedure, scientists were able to target a key brain ...

Maturing Plaques. The oldest plaques (left) contain β-sheets (red) and dense fibrillar cores (blue), while younger plaques (middle) lack dense cores, and the youngest (right) lack either. [Courtesy of ...

Drs Pavan Brahmbhatt and Amit Agarwal discuss best practices for managing amyloid-related imaging abnormalities in patients ...

AT-02 is a fusion protein of humanized immunoglobulin G1 with a pan amyloid-reactive peptide that facilitates binding of the antibody to amyloid deposits and subsequent removal. The Food and Drug ...

Amyloid fibrils appear in many neurodegenerative diseases, and scientists are eager to understand how they form and spread.